Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ

被引:34
|
作者
Shin, Sandra J. [1 ]
Lal, Aseem [2 ]
De Vries, Sandy [2 ]
Suzuki, Junko [2 ]
Roy, Ritu [3 ]
Hwang, E. Shelley [4 ]
Schnitt, Stuart J. [5 ]
Waldman, Frederic M. [2 ,3 ]
Chen, Yunn-Yi [6 ]
机构
[1] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA
[2] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Mt Zion Med Ctr, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[5] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[6] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
关键词
Florid lobular carcinoma in situ; Molecular profiling; INTRADUCTAL CARCINOMA; BREAST-CARCINOMA; NEOPLASIA; HYPERPLASIA; MANAGEMENT; FEATURES; LESIONS;
D O I
10.1016/j.humpath.2013.04.004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We evaluated genomic alterations and biomarker expression in 20 florid lobular carcinomas in situ using array-based comparative genomic hybridization and immunohistochemical analysis. The genetic characteristics of florid lobular carcinoma in situ were compared with 20 classic lobular carcinomas in situ and 21 pleomorphic lobular carcinomas in situ (which included 8 apocrine variants), from our previously published data performed on a similar array-based comparative genomic hybridization platform. All 20 florid lobular carcinoma in situ cases were E-cadherin negative, and 92% were positive for estrogen receptor. Cyclin D1 expression correlated significantly negatively with estrogen receptor expression and was higher in cases with cyclin D1 (CCND1) gene amplification. Compared with classic lobular carcinoma in situ, florid lobular carcinoma in situ displayed significantly more fraction genome alteration (mean, 0.109 versus 0.072; P = .007), fraction genome loss (mean, 0.06 versus 0.03; P = .007), numbers of breakpoints (mean, 11.55 versus 6.95; P = .002), numbers of chromosome with breakpoints (mean, 5.85 versus 3.8; P = .004), and higher numbers of amplifications (mean, 2.10 versus 0.25; P = .03). Interestingly, florid lobular carcinoma in situ had the same genetic complexity as apocrine pleomorphic lobular carcinoma in situ. Our study demonstrated that florid lobular carcinoma in situ shares the cytologic features, E-cadherin loss, and the lobular genetic signature of 1q gain and 16q loss found in classic lobular carcinoma in situ. However, this variant demonstrates more genomic alterations than classic lobular carcinoma in situ and shares the same genetic complexity as apocrine pleomorphic lobular carcinoma in situ. Our data support the conclusion that florid lobular carcinoma in situ is genetically more advanced compared with the indolent phenotype of classic lobular carcinoma in situ. This may explain the greater frequency of concurrent invasive carcinoma in florid lobular carcinoma in situ compared with classic lobular carcinoma in situ. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:1998 / 2009
页数:12
相关论文
共 50 条
  • [31] LOBULAR CARCINOMA IN SITU OF BREAST
    WARNER, E
    BENFIELD, JR
    JACOBSON, M
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1964, 42 (05) : 532 - &
  • [32] LOBULAR CARCINOMA IN SITU OF BREAST
    LEWISON, EF
    FINNEY, GG
    [J]. SURGERY GYNECOLOGY AND OBSTETRICS WITH INTERNATIONAL ABSTRACTS OF SURGERY, 1968, 126 (06): : 1280 - &
  • [33] Pleomorphic Lobular Carcinoma in Situ: A Single Institution Experience
    Brown, Kevin
    Kelly, Erinn Downs
    Al-hilli, Zahraa
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S460 - S461
  • [34] Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast
    Desai, Amita A.
    Jimenez, Rafael E.
    Hoskin, Tanya L.
    Day, Courtney N.
    Boughey, Judy C.
    Hieken, Tina J.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (10) : 3064 - 3068
  • [35] Diagnostic Excision Is Warranted for Pleomorphic Lobular Carcinoma In Situ
    Javid, Sara
    Allison, Kimberly
    Calhoun, Kristine
    Mann, Gary
    Byrd, David
    Anderson, Benjamin
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (02) : S175 - S175
  • [36] Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast
    Amita A. Desai
    Rafael E. Jimenez
    Tanya L. Hoskin
    Courtney N. Day
    Judy C. Boughey
    Tina J. Hieken
    [J]. Annals of Surgical Oncology, 2018, 25 : 3064 - 3068
  • [37] Genetic and phenotypic characteristics in pleomorphic lobular carcinoma in situ
    Chen, Y. Y.
    Vdasgupta, R.
    DeVries, S.
    Anderson, J.
    Wa, C.
    Fitzgibbons, P.
    Jacobs, T.
    MocGrogan, G.
    Pelerse, H.
    Vinceni-Salomon, A.
    Tokuyasu, T.
    Hwang, E. S.
    Schnilt, S.
    Waldman, F. M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S221 - S221
  • [38] Challenges in the management of pleomorphic lobular carcinoma in situ of the breast
    Masannat, Yazan A.
    Bains, Salena K.
    Pinder, Sarah E.
    Purushotham, Arnie D.
    [J]. BREAST, 2013, 22 (02): : 194 - 196
  • [39] Prognostic Value of Coexisting Lobular Carcinoma In Situ with Invasive Lobular Carcinoma
    Harbhajanka, A.
    Lamzabi, I.
    Syed, S.
    Slade, J. Macagba
    Gattuso, P.
    [J]. MODERN PATHOLOGY, 2014, 27 : 52A - 53A
  • [40] Pleomorphic apocrine lobular carcinoma in situ (PALCIS): Phenotypic and genetic study of a distinct-variant of lobular carcinoma in situ (LCIS)
    Chen, Y
    Fitzgibbons, P
    Jacobs, T
    MacGrogan, F
    Peterse, H
    Vincent-Salomon, A
    Wa, C
    DeVries, S
    Hwang, W
    Waldman, F
    Schmitt, S
    [J]. LABORATORY INVESTIGATION, 2005, 85 : 29A - 29A